Slide 1: Exchange filing cover letter: Investor Presentation
12th May 2023 (1) BSE Ltd. (2) National Stock Exchange of India Ltd. Listing Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, 5th floor Dalal Street Plot no. C/1, G Block Mumbai 400 001 Bandra Kurla Complex Scrip Code: 500087 Bandra (East), Mumbai - 400 051 Scrip Code: CIPLA (
Slide 2: Investor Presentation Q4FY23
Investor Presentation Q4FY23 12-05-2023 1
Slide 3: Disclaimer
DISCLAIMER Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties, pandemic and other factors that could cause actual
Slide 4: FY23: Growth momentum continues across focused markets
FY23: Growth momentum continues across focused markets Revenue (YoY Growth) EBITDA Margin R&D Spends2 Global Cipla Global 5% Global 22% ~6% 20% 11% Adj. margin1 ~23% of Revenue (YoY) Ex-Covid Revenue (Ex-Covid) 13% (YoY Growth) $733Mn 23% North (YoY Growth) One-India Chronic Share 300bps America lar
Slide 5: Continued strategic investments in FY23
Continued strategic investments in FY23 • Strengthens diabetes portfolio • Expansion into new category of weight • Entry into psoriasis portfolio • Brand size : ~INR 260+ Cr1 supplement • Innovator drug • Climbs 6 ranks from 14th to 8th in Anti- • Enhance growth via repositioning of Brand size : ~IN
Slide 6: Financial Performance – FY23
Financial Performance – FY23 Revenues INR 22,753 Cr EBITDA INR 5,027 Cr Revenue1 Break-up FY23 (Consolidated) API, 3% Others, 1% FY 23 vs FY22 (INR Cr) International Markets, Total Revenue from 22,753 4.5% 13% Operations EBITDA 5,027 9.8% India, 43% EBITDA % 22.1% 106 bps SAGA, 14% PAT 2,802 11.3% P
Slide 7: Q4FY23 Performance: Margin expands by ~600 bps vs Q4FY22
Q4FY23 Performance: Margin expands by ~600 bps vs Q4FY22 Continued strong traction in One-India and US differentiated portfolio KEY HIGHLIGHTS Global Revenue EBITDA Margin R&D Investment1 INR 5,739 Cr 20.5% 596 bps (YoY) 6.5% 15% 9% 14% 54% of overall YoY growth Reported Ex-covid revenue YoY growth
Slide 8: Financial Performance – Q4FY23
Financial Performance – Q4FY23 Revenues INR 5,739 Cr EBITDA INR 1,174 Cr Revenue1 Break-up Q4 FY23 (Consolidated) Actuals API, 2% Others, 1% vs Q4 FY22 (INR Cr) International Total Revenue from Markets, 5,739 9.1% Operations 14% EBITDA 1,174 54% India, 39% EBITDA % 20.5% 596 bps SAGA, PAT 526 45.2%
Slide 9: Continued focus on building balance sheet strength
Continued focus on building balance sheet strength INR Cr Total Debt1 Cash Balance2 Net Cash3 5,469 6,273 4,965 3,909 2,014 3,756 1,056 1,741 803 Mar'21 Mar'22 Mar'23 Mar'21 Mar'22 Mar'23 Mar'21 Mar'22 Mar'23 1. Total debt includes lease liabilities | 2. Includes cash and cash equivalents including
Slide 10: One India drives strong double-digit growth on an Ex-Covid basis
One India1 drives strong double-digit growth on an Ex-Covid basis at 13%; 3-year CAGR on an Ex-Covid basis stands at a solid ~19% (Ex-Covid) INR Cr (Ex-Covid) INR Cr CAGR 19% 9,874 2,259 8,752 1,951 16% 7,017 13% One-India YOY Growth FY 21 FY 22 FY 23 Q4 FY 22 Q4 FY 23 Branded Prescription Trade Gen
Slide 11: India Branded Prescriptions: Focused on making Big Brands Bigger
India Branded Prescriptions: Focused on making Big Brands Bigger Continued strong market position1 Strengthening Specialty in-licensing business INR Cr (non-covid) 539 3rd Overall IPM │5.4% market share 375 264 2nd Chronic IPM │8.3% market share 203 117 39 • Respiratory growing strong by 11.2% as pe
Slide 12: Strengthening reach and presence in Trade Generics
Strengthening reach and presence in Trade Generics Robust coverage to tier-2 and below markets Creating delight with digital connect ➢ Increasing penetration and retail #1 India’s largest trade generic business presence for new launches in 4 pilot states 5,500 Stockiest network ➢ Integrated web-base
Slide 13: Global consumer wellness franchise improving health outcomes
Global consumer wellness franchise improving health outcomes Demonstrated high growth in FY23; Building stronger brands in focused categories Consumer brands in India Consumer brands in South Africa INR 1,022 Cr ZAR 1,300 Mn 8% Share of Consumer business in Cipla for FY23 Levers: Brand building, dee
Slide 14: North America: Growth backed by expansion in share of differentiated products
North America: Growth backed by expansion in share of differentiated products 12th consecutive quarter of growth in revenue over previous year 250 $ Mn Lanreotide inj. Lenalidomide Launch launch 204 200 195 179 160 150 155 150 141 142 100 50 - Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Q3 FY23
Slide 15: North America: Traction in Core Respiratory formulations supported by Peptides
North America: Traction in Core Respiratory formulations supported by Peptides Key Business Highlights North America • Business crosses $ 730 mn+ revenue for the first time; highest ever $ Mn FY Y-o-Y quarterly sales of $ 204 mn 733 594 • Set-Up 505(b)(2) business unit with Lanreotide demonstrating
Slide 16: ANDA & NDA Portfolio & Pipeline (As on 31st March 2023)
ANDA & NDA Portfolio & Pipeline (As on 31st March 2023) 14 59 9 4 19 8 79 2 1 20 43 8 Approved Tentatively Under Approval ANDAs & NDAs Approved ANDAs ANDAs & NDAs 1 Cipla Ltd PEPFAR Invagen Partnered ANDAs/NDAs 161 1 31 74 266 Approved Tentatively Under Approval Total ANDAs & NDAs Approved ANDAs AND
Slide 17: SAGA: Focus on driving market beating growth and share of private market
SAGA1: Focus on driving market beating growth and share of private market continues Q4 YoY growth $ Mn FY YoY growth $ Mn 38 140 26 18 104 19 86 64 70 267 56 226 Q4 FY 22 Q4 FY 23 FY 22 FY 23 SA Private SA Tender Others (SSA & CGA) SA Private SA Tender Others (SSA & CGA) South Africa Brands launched
Slide 18: International Markets & API
International Markets & API International Markets API INR Cr 732 784 INR Cr 137 133 Q4 revenue Q4 Revenue $ Mn $ Mn 18 16 97 95 Q4 FY22 Q4 FY23 Q4 FY22 Q4 FY23 Key Business Highlights Key Business Highlights ❖ $ revenue impacted by currency volatility; 8% YoY ex-covid growth in INR terms ❖ Consisten
Slide 19: ESG Update
ESG Update Continued Progress on ESG Goals • Increased operational capacity: 55MWp • 2 partner agencies Baif and Myrada are captive solar access, 2.7 MVA of captive executing projects on ground. wind power project & 8 MWp Solar roof top • Creation of new water harvesting structures like farm bund, l
Slide 20: Profit and Loss statement summary
Profit and Loss statement summary Q4 FY23 FY 23 Particulars (INR Cr) (INR Cr) Rev enue from sale of products 5,666 22,473 Other operating income 73 280 Income from operations 5,739 22,753 Material cost 2,063 8,252 Employee benefits expense 965 3,830 Other expenses 1,537 5,644 Total expenses 4,566 17
Slide 21: Balance sheet summary
Balance sheet summary INR Cr Particulars Mar-23 Mar-22 Net Tangible Assets 5,740 5,609 Goodw ill & I ntangibles 4,514 4,841 I nv estments 573 356 Other non current assets 352 307 Adv ance tax assets (net) 531 463 Deferred tax assets (net) 293 205 I nv entories 5,156 5,350 Cash and Cash Equiv alents
Slide 22: Thank You
Thank You Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Naveen Bansal Investor.Relations@cipla.com Ajinkya Pandharkar Investor.Relations@cipla.com For more information please visit www.cipla.